Momelotinib-2,2,6,6-d4
Modify Date: 2024-04-06 20:23:18
Momelotinib-2,2,6,6-d4 structure
|
Common Name | Momelotinib-2,2,6,6-d4 | ||
|---|---|---|---|---|
| CAS Number | 1619927-64-8 | Molecular Weight | 418.48 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H18D4N6O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Momelotinib-2,2,6,6-d4Momelotinib-2,2,6,6-d4 (CYT387-2,2,6,6-d4) is the deuterium labeled Momelotinib (HY-10961). Momelotinib (CYT387) is an orally acitve and ATP-competitive JAK1/JAK2 inhibitor with IC50s of 11 nM and 18 nM, respectively[1][2]. |
| Name | Momelotinib-2,2,6,6-d4 |
|---|
| Description | Momelotinib-2,2,6,6-d4 (CYT387-2,2,6,6-d4) is the deuterium labeled Momelotinib (HY-10961). Momelotinib (CYT387) is an orally acitve and ATP-competitive JAK1/JAK2 inhibitor with IC50s of 11 nM and 18 nM, respectively[1][2]. |
|---|---|
| Related Catalog | |
| Target |
JAK1:11 nM (IC50) JAK2:18 nM (IC50) |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
| Molecular Formula | C23H18D4N6O2 |
|---|---|
| Molecular Weight | 418.48 |